Harmony Biosciences Holdings, Inc. (HRMY) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 9:30 AM EDT
Company Participants
Jeffrey Dayno – President, CEO & Director
Adam Zaeske – Executive VP & Chief Commercial Officer
Kumar Budur – Executive VP and Chief Medical & Scientific Officer
Conference Call Participants
Ami Fadia – Needham & Company, LLC, Research Division
Presentation
Ami Fadia
Needham & Company, LLC, Research Division
Good morning, everyone. I’m Ami Fadia, biotech analyst here at Needham. It’s my pleasure to be hosting the Harmony Bioscience team today. I have with me Jeff Dayno, who’s the CEO of the company; along with Kumar Budur, Chief Scientific Officer; and Adam Zaeske, Chief Commercial Officer. Thanks, all 3 of you for taking the time to be with us today.
Question-and-Answer Session
Ami Fadia
Needham & Company, LLC, Research Division
Maybe if I could ask Jeff, if you could kick us off with some opening remarks, some priorities for this year, and then we can take it from there?
Jeffrey Dayno
President, CEO & Director
Yes. Sure, Ami. Yes, Ami. And on behalf of the Harmony team, thank you once again for the invitation to Needham’s Virtual Healthcare Conference. And we are very excited for what is coming this year, that sets us up for both near-term and long-term growth and value creation. As for some of our key priorities, just to sort of walk through, starting with WAKIX. So we are on track to achieve over $1 billion in net revenue for WAKIX in its sixth year on the market, which provides us with a very solid foundation, I think, as many are aware.
In our pitolisant next-gen programs, pitolisant GR gastro-resistant is on track for NDA submission this quarter to extend the pitolisant franchise with a target PDUFA date in the first
